Exelixis
EXEL
#1694
Rank
S$15.47 B
Marketcap
S$57.49
Share price
-0.02%
Change (1 day)
19.66%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): S$3.09

According to Exelixis's latest financial reports the company's current EPS (TTM) is S$3.08. In 2023 the company made an earnings per share (EPS) of S$0.85 an increase over its 2022 EPS that were of S$0.74.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$3.09
2023S$0.8514.61%
2022S$0.74-22.97%
2021S$0.96100%
2020S$0.48-65.09%
2019S$1.37-53.91%
2018S$2.98333.96%
2017S$0.69-260.61%
2016S-$0.43-58.75%
2015S-$1.04-42.45%
2014S-$1.805.3%
2013S-$1.71

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
S$4.66 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
S$4.80 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$9.84 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$3.85 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$16.89 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
S$13.53 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$2.23-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
S-$4.76-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S-$1.09-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA